Psychopharmacologic algorithms for adults with developmental disabilities and difficult-to-diagnose behavioral disorders

Psychiatric Annals

Volumn 29, Issue 5, 1999, Pages 302-314

  Mikkelsen, Edwin J ^a,b,c,d   McKenna, Leo ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Mentor   (United States)

^c Massachusetts Mental Heath Center   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033407698     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19990501-11     Document Type: Article

References (42)

1. Mikkelsen EJ. Risk-benefit analysis in the use of psychopharmacologic interventions for difficult-to-diagnose behavioral disorders in individuals with mental retardation. Psychiatric Annals. 1997;27:207-212.
2. Aman MG, Singh NN. Aberrant Behavior Checklist Manual. East Aurora, NY: Slosson Educational Publications; 1986.
3. Aman MG, Singh NN. Aberrant Behavior Checklist Community Supplementary Manual. East Aurora, NY: Slosson Educational Publications; 1994.
4. Nihira K, Leland H, Lambert N. Adaptive Behavior Scale: Residential and Community. Washington, DC: American Association of Mental Retardation; 1993.
5. Matson JL, Coe A, Gardner WI, Sovner R. A factor analytic study of the diagnostic assessment for the severely handicapped scale. J Nerv Ment Dis. 1991;179:553-557.
6. Einfeld SL, Tonge BJ. The Developmental Behaviour Checklist: the development and validation of an instrument for the assessment of behavioral and emotional disturbance in children and adolescents with mental retardation. J Autism Dev Disord. 1995;25:81-104.
7. Strohmer DC, Prout HT. The Emotional Problems Scales. Odessa, FL: Psychological Assessment Resources; 1991.
8. Matson JL. The PIMRA Manual, 2nd ed. Worthington, OH: IDS Publishing; 1997.
9. Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University Nisonger Center; 1998.
10. Fahs JJ. Habilitative Neuropsychiatry: Psychopharmacology (1985-1996): A Reference Guide. Kingston, NY: National Association of Dual Diagnosis; 1996.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
12. Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989;50:382-384.
13. Mikkelsen EJ, Albert LG, Emens M, Rubin E. The efficacy of antidepressant medication for individuals with mental retardation. Psychiatric Annals. 1997;27:198-206.
14. Fuller RW. Fluoxetine effects on serotonin function and aggressive behavior. Ann N Y Acad Sci. 1996;794:90-97.
15. Ratey JJ, Mikkelsen E, Sorgi P, et al. Autism: the treatment of aggressive behaviors. J Clin Psychopharmacol. 1987; 7:35-41.
16. Ratey JJ, Mikkelsen EJ, Smith GB, et al. β-blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol. 1986;6:103-107.
17. Ruedrich SL. Beta-adrenergic blocking medications for treatment of rage outbursts in mentally retarded persons. Seminars in Clinical Neuropsychiatry. 1996;1:115-121.
18. Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol. 1990;1:87-102.
19. Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322-327.
20. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:77-82.
21. Sovner R. Thioridazine withdrawal-induced behavioral deterioration treated with clonidine: two case reports. Ment Retard. 1995;33:221-225.
22. Langee HR. A retrospective study of mentally retarded patients with behavioral disorders who were treated with carbamazapine. Am J Ment Retard. 1989;93:640-643.
23. Kastnert T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol. 1993;13:448-451.
24. Mattes JA. Valproic acid for nonaffective aggression in the mentally retarded. J Nerv Ment Dis. 1992;180:601-602.
25. Sovner R. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. J Clin Psychiatry. 1989;50:40-13.
26. McDougle CJ, Brodkin ES, Teung PP, Naylor ST, Cohen DJ, Price LH. Risperidone in adults with autism or pervasive developmental disorder. J Clin Adolesc Psychopharmacol. 1995;5:273-282.
27. Purdon SE, Lit W, LaBelle A, Jones BDW. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry. 1994;39:400-405.
28. Vanden Borre R, Vermote R, Buttiens M, et al. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 1993;87:167-171.
29. Connor DF, Posever TA. A brief review of atypical antipsychotics in individuals with developmental disability. Mental Health Aspects of Developmental Disabilities. 1998;1:93-102.
30. Cohen SA, Underwood MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry. 1994;55:440-444.
31. Rubin M, Langa A. Clozapine, mental retardation, and severe psychiatric illness: clinical response in the first year. Harv Rev Psychiatry. 1995;3:293-294.
32. Sajatovic M, Ramirez, LF, Kenny JT, Meltzer HY. The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Compr Psychiatry. 1994;35:29-33.
33. Mikkelsen EJ, Albert LG, Upadhyaya A. Neuroleptic-withdrawal cachexia. N Engl J Med. 1988;318:929.
34. Mikkelsen EJ. Low-dose haloperidol for stereotypic self-injurious behavior in the mentally retarded. N Engl J Med. 1986;315:398-399.
35. Craft M, Ismail IA, Krishnamurth D, et al. Lithium in the treatment of aggression in mentally handicapped patients: a double-blind trial. Br J Psychiatry. 1987;150: 685-689.
36. Langee HR. Retrospective study of lithium use for institutionalized mentally retarded individuals with behavior disorders. Am J Ment Retard. 1990;94:448-452.
37. Pary RJ. Towards defining adequate lithium trials for individuals with mental retardation and mental illness. Am J Ment Retard. 1991;95:681-691.
38. Spreat S, Behar D, Reneski B, Miazzo P. Lithium carbonate for aggression in mentally retarded persons. Compr Psychiatry. 1989;30:505-511.
39. Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry. 1998;59:426-429.
40. Barak Y, Ring A, Levy D, Granek I, Szor H, Elizur A. Disabling compulsions in 11 mentally retarded adults: an open trial of clomipramine SR. J Clin Psychiatry. 1995;56:459-461.
41. Garber HJ, McGonigle JJ, Slomka GT, Monteverde E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 1992;31:1157-1160.
42. Lewis MH, Bodfish JW, Powell SB, Golden RN. Clomipramine treatment for stereotypic and related repetitive movement disorders associated with mental retardation. Am J Ment Retard. 1995;100:299-312.